Lo / Ovral-28 Side effects

• Side effects of Lo / Ovral-28 in details
• Lo / Ovral-28 contraindications
• Lo / Ovral-28 reviews

What are the possible side effects of Lo / Ovral-28?

Get emergency medical help if you have any of these signs of an allergic reaction to Lo/Lo / Ovral-28-28: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Stop using Lo/Lo / Ovral-28-28 and call your doctor at once if you have a serious side effect such as:

• sudden numbness or weakness, especially on one side of the body;

• sudden and severe headache, confusion, problems with vision, speech, or balance;

• chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;

• sudden cough, wheezing, rapid breathing, coughing up blood;

• pain, swelling, warmth, or redness in one or both legs;

• a change in the pattern or severity of migraine headaches;

• nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);

• swelling in your hands, ankles, or feet;

• a breast lump; or

• symptoms of depression (sleep problems, weakness, tired feeling, mood changes).

Less serious Lo/Lo / Ovral-28-28 side effects may include:

• mild nausea (especially when you first start taking this medicine), vomiting, bloating, stomach cramps;

• breast tenderness or swelling, nipple discharge;

• freckles or darkening of facial skin, increased hair growth, loss of scalp hair;

• changes in weight or appetite;

• problems with contact lenses;

• vaginal itching or discharge; or

• changes in your menstrual periods, decreased sex drive.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Side effects of Lo / Ovral-28 in details

An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives :

• Thrombophlebitis

• Arterial thromboembolism

• Pulmonary embolism

• Myocardial infarction

• Cerebral hemorrhage

• Cerebral thrombosis

• Hypertension

• Gallbladder disease

• Hepatic adenomas, carcinomas or benign liver tumors

There is evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed:

• Mesenteric thrombosis

• Retinal thrombosis

The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related:

• Nausea

• Vomiting

• Gastrointestinal symptoms (such as abdominal cramps and bloating)

• Breakthrough bleeding

• Spotting

• Change in menstrual flow

• Amenorrhea

• Temporary infertility after discontinuation of treatment

• Edema

• Melasma which may persist

• Breast changes: tenderness, enlargement, secretion

• Change in weight (increase or decrease)

• Change in cervical erosion and secretion

• Diminution in lactation when given immediately postpartum

• Cholestatic jaundice

• Migraine

• Rash (allergic)

• Mental depression

• Reduced tolerance to carbohydrates

• Vaginal candidiasis

• Change in corneal curvature (steepening)

• Intolerance to contact lenses

The following adverse reactions have been reported in users of oral contraceptives and the association has been neither confirmed nor refuted:

• Pre-menstrual syndrome

• Cataracts

• Changes in appetite

• Cystitis-like syndrome

• Headache

• Nervousness

• Dizziness

• Hirsutism

• Loss of scalp hair

• Erythema multiforme

• Erythema nodosum

• Hemorrhagic eruption

• Vaginitis

• Porphyria

• Impaired renal function

• Hemolytic uremic syndrome

• Budd-Chiari syndrome

• Acne

• Changes in libido

• Colitis

What is the most important information I should know about Lo / Ovral-28?

• Lo / Ovral-28 may cause dizziness. These effects may be worse if you take it with alcohol or certain medicines. Use Lo / Ovral-28 with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.
• Follow your doctor's instructions for examining your own breasts and report any lumps immediately.
• If you will be having surgery or will be confined to a bed or chair for a long period of time (such as a long plane flight), notify your doctor 3 to 4 weeks ahead of time. Special precautions may need to be taken in these circumstances while taking Lo / Ovral-28.
• Lo / Ovral-28 may cause dark skin patches on your face. Exposure to the sun may make these patches darker. If patches develop, use a sunscreen or protected clothing when exposed to the sun, sunlamps, or tanning booths.
• Use of Lo / Ovral-28 will not prevent the spread of sexually transmitted diseases (STDs).
• Bleeding or spotting may occur while taking Lo / Ovral-28. Do not stop taking Lo / Ovral-28 if this occurs. If bleeding or spotting continues for more than 7 days or is heavy, contact your doctor.
• Lo / Ovral-28 may increase the risk of stroke, heart attack, blood clots, high blood pressure, or similar problems. The risk may be greater if you smoke.
• Lo / Ovral-28 may interfere with certain lab tests. Be sure your doctor and lab personnel know you are taking Lo / Ovral-28.
• Taking certain antibiotics, anticonvulsants, or other medicines, as listed in the interactions section, while you are using Lo / Ovral-28 may decrease the effectiveness of Lo / Ovral-28. To prevent pregnancy, use an extra form of birth control until your next period.
• If you wear contact lens and you develop problems with them, contact your doctor.
• If you miss your period during the week of inactive pills, call your doctor immediately. A missed period may indicate that you are pregnant.
• Lo / Ovral-28 may take time to wear off after your last dose. You may not be able to become pregnant for several months after stopping Lo / Ovral-28. Discuss any concerns with your doctor or pharmacist.
• Lab tests, including PAP tests, may be performed while you use Lo / Ovral-28. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.
• Lo / Ovral-28 is not recommended for use in CHILDREN who have not had their first menstrual period. Safety and effectiveness in this age group have not been confirmed.
• PREGNANCY and BREAST-FEEDING: Do not use Lo / Ovral-28 if you are pregnant. If you think you may be pregnant, contact your doctor right away. Lo / Ovral-28 is found in breast milk. Do not breast-feed while taking Lo / Ovral-28.

Lo / Ovral-28 contraindications

Combination oral contraceptives should not be used in women with any of the following conditions: - Thrombophlebitis or thromboembolic disorders - A past history of deep-vein thrombophlebitis or thromboembolic disorders - Cerebral-vascular or coronary-artery disease (current or history) - Thrombogenic valvulopathies - Thrombogenic rhythm disorders - Major surgery with prolonged immobilization - Diabetes with vascular involvement - Headaches with focal neurological symptoms - Uncontrolled hypertension Known or suspected carcinoma of the breast or personal history of breast cancer - Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia - Undiagnosed abnormal genital bleeding - Cholestatic jaundice of pregnancy or jaundice with prior pill use - Hepatic adenomas or carcinomas, or active liver disease, as long as liver function has not returned to normal - Known or suspected pregnancy - Hypersensitivity to any of the components of Lo/Lo / Ovral-28

References

1. DailyMed. "ETHINYL ESTRADIOL; NORETHINDRONE ACETATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. DailyMed. "ETHINYL ESTRADIOL; NORGESTREL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
3. DTP/NCI. "ethinyl estradiol: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Lo / Ovral-28 are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Lo / Ovral-28. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 13 here

Information checked by Dr. Sachin Kumar, MD Pharmacology